4 results about "Hepatectomy" patented technology

Methods and uses of increasing or accelerating liver regeneration in a subject in need thereof are provided. In some aspects, such methods and uses comprise administering an effective amount of an androgen receptor inhibitor to a subject in need thereof, including, but not limited to, a subject suffering from one or more risk factors of post-hepatectomy liver failure. Any androgen receptor is contemplated for use in the methods described herein including, but not limited to, enzalutamide, apalutamide, bicalutamide, darolutamide, flutamide, nilutamide, or proxalutamide.

The application discloses a kind of microfiber scaffolds, organoid tissue patches and preparation method and application thereof.The microfiber scaffold is prepared using melt electrospinning process, by introducing stepwise translation deposition path in the same deposition plane, so that the continuous deposition of multiple microfibers forms stable convergence node structure at predetermined position, thereby constructing microfiber network with regular pore and continuous support topology.The stepwise translation deposition includes at least one repeated deposition with preset in-plane offset after the completion of the first pass fiber deposition, to reduce the electrostatic interference between fibers and promote node formation.The scaffold structure is stable, open and thin, suitable as a tissue engineering support structure.The application also provides an organoid tissue patch composed of the scaffold loaded organoids and a construction method thereof, which can be used to cover tissue injury interface, such as post-hepatectomy section repair.

This invention discloses the application of PIEZO1 inhibitors in the preparation of drugs to inhibit liver regeneration. Specifically, this invention relates to the application of the PIEZO1-specific inhibitor Dooku1 in the preparation of drugs to inhibit liver regeneration after hepatectomy. This invention also provides the application of Dooku1 in the preparation of reagents for constructing animal models of liver aplastic disorder. Experiments of this invention show that administration of Dooku1 significantly reduces the liver weight / body weight ratio, inhibits hepatocyte proliferation (significantly decreasing Ki67 positivity rate), and is accompanied by an increase in serum ALT and AST levels, successfully constructing a target-specific and reproducible animal model of liver aplastic disorder. This invention is the first to apply PIEZO1 inhibitors to inhibit liver regeneration, filling the technological gap in negatively regulating liver regeneration through inhibition of the PIEZO1 pathway, and providing potential candidate drugs and intervention strategies for pathological conditions requiring inhibition of abnormal liver hyperplasia after liver transplantation and hepatectomy.

The application discloses a biomarker of liver ischemia-reperfusion injury based on proteomics, and the biomarker is neutrophil granule protein (NGP), which can be used for early diagnosis and prevention of post-hepatectomy complications, prognosis monitoring and judgment, etc.